Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

CDEK: Clinical Drug Experience Knowledgebase.

Griesenauer RH, Schillebeeckx C, Kinch MS.

Database (Oxford). 2019 Jan 1;2019. pii: baz087. doi: 10.1093/database/baz087.

2.

2018 in review: FDA approvals of new molecular entities.

Kinch MS, Griesenauer RH.

Drug Discov Today. 2019 Sep;24(9):1710-1714. doi: 10.1016/j.drudis.2019.05.022. Epub 2019 May 31.

PMID:
31158510
3.

Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases.

Griesenauer RH, Schillebeeckx C, Kinch MS.

Drug Discov Today. 2019 Apr;24(4):1010-1016. doi: 10.1016/j.drudis.2019.01.010. Epub 2019 Jan 25. Review.

PMID:
30690196
4.

Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery.

Kinch MS, Kinch GA, Griesenauer RH.

Drug Discov Today. 2019 Feb;24(2):382-389. doi: 10.1016/j.drudis.2018.09.006. Epub 2018 Sep 14.

PMID:
30223039
5.

2017 in review: FDA approvals of new molecular entities.

Kinch MS, Griesenauer RH.

Drug Discov Today. 2018 Aug;23(8):1469-1473. doi: 10.1016/j.drudis.2018.05.011. Epub 2018 May 8. Review.

PMID:
29751111
6.

NIH Support for FDA-Approved Medicines.

Griesenauer RH, Moore R, Kinch MS.

Cell Chem Biol. 2017 Nov 16;24(11):1315-1316. doi: 10.1016/j.chembiol.2017.11.002. No abstract available.

7.

An overview of FDA-approved vaccines & their innovators.

Griesenauer RH, Kinch MS.

Expert Rev Vaccines. 2017 Dec;16(12):1253-1266. doi: 10.1080/14760584.2017.1383159. Epub 2017 Sep 25. Review.

8.

2016 in review: FDA approvals of new molecular entities.

Griesenauer RH, Kinch MS.

Drug Discov Today. 2017 Nov;22(11):1593-1597. doi: 10.1016/j.drudis.2017.06.011. Epub 2017 Jul 4.

PMID:
28687460
9.

Analysis of FDA-approved imaging agents.

Kinch MS, Woodard PK.

Drug Discov Today. 2017 Jul;22(7):1077-1083. doi: 10.1016/j.drudis.2017.03.006. Epub 2017 Mar 21. Review.

10.

Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry.

Kinch MS, Moore R.

Cell Chem Biol. 2016 Jun 23;23(6):644-53. doi: 10.1016/j.chembiol.2016.05.013. Review.

11.

2015 in review: FDA approval of new drugs.

Kinch MS.

Drug Discov Today. 2016 Jul;21(7):1046-50. doi: 10.1016/j.drudis.2016.04.008. Epub 2016 Apr 19.

PMID:
27109618
12.

An analysis of original research contributions toward FDA-approved drugs.

Patridge EV, Gareiss PC, Kinch MS, Hoyer DW.

Drug Discov Today. 2015 Oct;20(10):1182-7. doi: 10.1016/j.drudis.2015.06.006. Epub 2015 Jun 22.

PMID:
26113307
13.

2014 in review: FDA approval of new drugs.

Kinch MS.

Drug Discov Today. 2017 Apr;22(4):620-624. doi: 10.1016/j.drudis.2015.06.004. Epub 2015 Jun 19.

PMID:
26100738
14.

A history of drug development in four acts.

Kinch MS, Hoyer D.

Drug Discov Today. 2015 Oct;20(10):1163-8. doi: 10.1016/j.drudis.2015.04.003. Epub 2015 Apr 20. No abstract available.

PMID:
25908577
15.

An analysis of FDA-approved drugs for inflammation and autoimmune diseases.

Kinch MS, Merkel J.

Drug Discov Today. 2015 Aug;20(8):920-3. doi: 10.1016/j.drudis.2015.02.006. Epub 2015 Feb 17.

PMID:
25701283
16.

An analysis of FDA-approved drugs for neurological disorders.

Kinch MS.

Drug Discov Today. 2015 Sep;20(9):1040-3. doi: 10.1016/j.drudis.2015.02.003. Epub 2015 Feb 11.

PMID:
25681791
17.

An analysis of FDA-approved drugs for metabolic diseases.

Kinch MS, Umlauf S, Plummer M.

Drug Discov Today. 2015 Jun;20(6):648-51. doi: 10.1016/j.drudis.2015.02.002. Epub 2015 Feb 11.

PMID:
25680688
18.

An analysis of FDA-approved drugs: natural products and their derivatives.

Patridge E, Gareiss P, Kinch MS, Hoyer D.

Drug Discov Today. 2016 Feb;21(2):204-7. doi: 10.1016/j.drudis.2015.01.009. Epub 2015 Jan 21.

PMID:
25617672
19.

New drug discovery: extraordinary opportunities in an uncertain time.

Kinch MS, Flath R.

Drug Discov Today. 2015 Nov;20(11):1288-92. doi: 10.1016/j.drudis.2014.12.008. Epub 2014 Dec 17.

PMID:
25528676
20.

Sources of innovation: an assessment of intellectual property.

Kinch MS, Raffo J.

Drug Discov Today. 2015 May;20(5):500-4. doi: 10.1016/j.drudis.2014.12.002. Epub 2014 Dec 9.

PMID:
25499663
21.

Target selection for FDA-approved medicines.

Kinch MS, Hoyer D, Patridge E, Plummer M.

Drug Discov Today. 2015 Jul;20(7):784-9. doi: 10.1016/j.drudis.2014.11.001. Epub 2014 Nov 11. Review.

PMID:
25462532
22.

Post-approval fate of pharmaceutical companies.

Kinch MS.

Drug Discov Today. 2015 Feb;20(2):170-4. doi: 10.1016/j.drudis.2014.10.013. Epub 2014 Nov 4.

PMID:
25448760
23.

An overview of FDA-approved biologics medicines.

Kinch MS.

Drug Discov Today. 2015 Apr;20(4):393-8. doi: 10.1016/j.drudis.2014.09.003. Epub 2014 Sep 16. Review.

PMID:
25220442
24.

An analysis of FDA-approved drugs for pain and anesthesia.

Kinch MS.

Drug Discov Today. 2015 Jan;20(1):3-6. doi: 10.1016/j.drudis.2014.09.002. Epub 2014 Sep 15.

PMID:
25218931
25.

An analysis of FDA-approved drugs for cardiovascular diseases.

Kinch MS, Surovtseva Y, Hoyer D.

Drug Discov Today. 2016 Jan;21(1):1-4. doi: 10.1016/j.drudis.2014.09.001. Epub 2014 Sep 15.

PMID:
25218930
26.

An analysis of FDA-approved drugs for psychiatric disorders.

Kinch MS, Patridge E.

Drug Discov Today. 2015 Mar;20(3):292-5. doi: 10.1016/j.drudis.2014.08.013. Epub 2014 Sep 6. No abstract available.

PMID:
25200172
27.

An analysis of FDA-approved drugs for oncology.

Kinch MS.

Drug Discov Today. 2014 Dec;19(12):1831-5. doi: 10.1016/j.drudis.2014.08.007. Epub 2014 Aug 27.

PMID:
25172803
28.

An analysis of FDA-approved drugs for infectious disease: antibacterial agents.

Kinch MS, Patridge E, Plummer M, Hoyer D.

Drug Discov Today. 2014 Sep;19(9):1283-7. doi: 10.1016/j.drudis.2014.07.005. Epub 2014 Jul 17.

PMID:
25043770
29.

Trends in pharmaceutical targeting of clinical indications: 1930-2013.

Kinch MS, Merkel J, Umlauf S.

Drug Discov Today. 2014 Nov;19(11):1682-1685. doi: 10.1016/j.drudis.2014.05.021. Epub 2014 May 29.

PMID:
24881779
30.

An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs.

Kinch MS, Patridge E.

Drug Discov Today. 2014 Oct;19(10):1510-3. doi: 10.1016/j.drudis.2014.05.012. Epub 2014 May 28.

PMID:
24880109
31.

The rise (and decline?) of biotechnology.

Kinch MS.

Drug Discov Today. 2014 Nov;19(11):1686-1690. doi: 10.1016/j.drudis.2014.04.006. Epub 2014 Apr 18.

PMID:
24747562
32.

An overview of FDA-approved new molecular entities: 1827-2013.

Kinch MS, Haynesworth A, Kinch SL, Hoyer D.

Drug Discov Today. 2014 Aug;19(8):1033-9. doi: 10.1016/j.drudis.2014.03.018. Epub 2014 Mar 26. Review.

PMID:
24680947
33.

Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation.

Reiske H, Sui B, Ung-Medoff H, Donahue R, Li WB, Goldblatt M, Li L, Kinch MS.

Anal Quant Cytol Histol. 2010 Apr;32(2):61-9.

PMID:
20701074
34.

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD.

Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3.

PMID:
20602165
35.

Antiviral activity of a small-molecule inhibitor of filovirus infection.

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S.

Antimicrob Agents Chemother. 2010 May;54(5):2152-9. doi: 10.1128/AAC.01315-09. Epub 2010 Mar 8.

36.

FGI-104: a broad-spectrum small molecule inhibitor of viral infection.

Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher-Hennings J, Olinger GG, Goldblatt M.

Am J Transl Res. 2009 Jan 5;1(1):87-98.

37.

Identification of PTCH1 requirement for influenza virus using random homozygous gene perturbation.

Li WB, Zhu J, Hart B, Sui B, Weng K, Chang S, Geiger R, Torremorell M, Mileham A, Gladney C, Mellancamp MA, Li L, Yunus A, Goldblatt M, Kinch MS.

Am J Transl Res. 2009 Apr 12;1(3):259-66.

38.

Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation.

Mao H, Chen H, Fesseha Z, Chang S, Ung-Medoff H, Van Dyke J, Kohli M, Li WB, Goldblatt M, Kinch MS.

Virol J. 2009 Sep 29;6:154. doi: 10.1186/1743-422X-6-154.

39.

Development of a broad-spectrum antiviral with activity against Ebola virus.

Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S.

Antiviral Res. 2009 Sep;83(3):245-51. doi: 10.1016/j.antiviral.2009.06.001. Epub 2009 Jun 10.

PMID:
19523489
40.

Function-first approaches to improve target identification in cancer.

Kinch MS, Kohli M, Goldblatt M, Li WB.

Future Oncol. 2009 Jun;5(5):617-23. doi: 10.2217/fon.09.42. Review.

PMID:
19519202
41.

The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza.

Sui B, Bamba D, Weng K, Ung H, Chang S, Van Dyke J, Goldblatt M, Duan R, Kinch MS, Li WB.

Virology. 2009 May 10;387(2):473-81. doi: 10.1016/j.virol.2009.02.046. Epub 2009 Mar 27.

42.

Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.

Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ.

J Immunol. 2008 Dec 1;181(11):7721-7.

43.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

44.

EphA2 overexpression promotes ovarian cancer growth.

Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK.

Cancer Biol Ther. 2008 Jul;7(7):1098-103. Epub 2008 Apr 19.

45.

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.

Cancer Res. 2007 Apr 15;67(8):3927-35.

46.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA.

Mol Cancer Ther. 2006 Dec;5(12):3122-9.

47.

EphA2 overexpression is associated with angiogenesis in ovarian cancer.

Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK.

Cancer. 2007 Jan 15;109(2):332-40.

48.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
49.

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1357-60. Epub 2006 Oct 31.

PMID:
16969087
50.

VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry.

Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ.

Cancer Biol Ther. 2006 Feb;5(2):228-33. Epub 2006 Feb 14.

PMID:
16481735

Supplemental Content

Loading ...
Support Center